An Ethical and Financial Obligation for Sickle Cell Disease Gene Therapy in the United States

Ann Intern Med. 2024 Jan;177(1):85-86. doi: 10.7326/M23-2428. Epub 2023 Dec 5.

Authors

Austin Wesevich¹, Monica E Peek², Mark J Ratain¹

Affiliations

¹ Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois (A.W., M.J.R.).
² Section of General Internal Medicine, Department of Medicine, University of Chicago, Chicago, Illinois (M.E.P.).

PMID: 38048579
DOI: 10.7326/M23-2428

No abstract available

Publication types

Editorial
Research Support, N.I.H., Extramural

MeSH terms

Anemia, Sickle Cell* / genetics
Anemia, Sickle Cell* / therapy
Genetic Therapy* / economics
Genetic Therapy* / ethics
Humans
United States

Grants and funding

T32 CA009566/CA/NCI NIH HHS/United States